These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37832923)

  • 21. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B.
    Ma SW; Huang X; Li YY; Tang LB; Sun XF; Jiang XT; Zhang YX; Sun J; Liu ZH; Abbott WG; Dong YH; Naoumov NV; Hou JL
    J Hepatol; 2012 Apr; 56(4):775-81. PubMed ID: 22173154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Telbivudine versus lamivudine in patients with chronic hepatitis B.
    Lai CL; Gane E; Liaw YF; Hsu CW; Thongsawat S; Wang Y; Chen Y; Heathcote EJ; Rasenack J; Bzowej N; Naoumov NV; Di Bisceglie AM; Zeuzem S; Moon YM; Goodman Z; Chao G; Constance BF; Brown NA;
    N Engl J Med; 2007 Dec; 357(25):2576-88. PubMed ID: 18094378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B.
    Song MJ; Song DS; Kim HY; Yoo SH; Bae SH; Choi JY; Yoon SK; Paik YH; Lee JS; Lee HW; Kim HJ
    World J Gastroenterol; 2012 Nov; 18(43):6277-83. PubMed ID: 23180949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
    Seto WK; Wong DK; Fung J; Huang FY; Lai CL; Yuen MF
    Hepatology; 2013 Sep; 58(3):923-31. PubMed ID: 23468172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors associated with the biphasic kinetics of serum HBV RNA in patients with HBeAg-positive chronic hepatitis B treated with nucleos(t)ide analogues.
    Liu S; Liu Z; Li W; Zhou B; Liang X; Fan R; Deng R; Hou J; Sun J
    Aliment Pharmacol Ther; 2020 Aug; 52(4):692-700. PubMed ID: 32613672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Letter: improved alanine aminotransferase level in patients with chronic hepatitis B without cirrhosis and low viral load treated with nucleotide/nucleoside analogues.
    Jang TY
    Aliment Pharmacol Ther; 2023 Mar; 57(5):587-588. PubMed ID: 36786461
    [No Abstract]   [Full Text] [Related]  

  • 27. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
    Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
    Buster EH; Schalm SW; Janssen HL
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of HBsAg quantification for monitoring natural history and treatment outcome.
    Martinot-Peignoux M; Lapalus M; Asselah T; Marcellin P
    Liver Int; 2013 Feb; 33 Suppl 1():125-32. PubMed ID: 23286856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sustained off-treatment viral control is associated with high hepatitis B surface antigen seroclearance rates in Caucasian patients with nucleos(t)ide analogue-induced HBeAg seroconversion.
    Van Hees S; Chi H; Hansen B; Bourgeois S; Van Vlierberghe H; Sersté T; Francque S; Wong D; Sprengers D; Moreno C; Nevens F; Janssen HLA; Vanwolleghem T
    J Viral Hepat; 2019 Jun; 26(6):766-769. PubMed ID: 30801868
    [No Abstract]   [Full Text] [Related]  

  • 31. Effectiveness of antiviral treatment in HBeAg-negative chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase: a retrospective study.
    Wei S; Hu M; Chen H; Xie Q; Wang P; Li H; Peng J
    BMC Gastroenterol; 2022 Aug; 22(1):387. PubMed ID: 35978283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Letter: improved alanine aminotransferase level in non-cirrhotic and low-viral load chronic hepatitis B patients treated with nucleotide/nucleoside analogues -authors' reply.
    Huang R; Wang J; Yan X; Zhu C; Wu C
    Aliment Pharmacol Ther; 2023 Mar; 57(5):589-590. PubMed ID: 36786453
    [No Abstract]   [Full Text] [Related]  

  • 33. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
    Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
    Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severity of Hepatitis B Relapse After Cessation of Nucleos(t)ide Analog: Need a Closer Look!
    Jindal A
    Clin Gastroenterol Hepatol; 2022 Aug; 20(8):1885-1886. PubMed ID: 34508869
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinical characteristics of and factors related to relapse in chronic hepatitis B patients after nucleoside analogues withdrawal].
    Chen L; Li XL; Gan QR; Zhang DQ; Lin RS; Lin MH
    Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):825-8. PubMed ID: 24331691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients.
    Cai W; Xie Q; An B; Wang H; Zhou X; Zhao G; Guo Q; Gu R; Bao S
    J Clin Virol; 2010 May; 48(1):22-6. PubMed ID: 20233672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
    Viganò M; Mangia G; Lampertico P
    Liver Int; 2014 Feb; 34 Suppl 1():120-6. PubMed ID: 24373088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes.
    Van Hees S; Bourgeois S; Van Vlierberghe H; Sersté T; Francque S; Michielsen P; Sprengers D; Reynaert H; Henrion J; Negrin Dastis S; Delwaide J; Lasser L; Decaestecker J; Orlent H; Janssens F; Robaeys G; Colle I; Stärkel P; Moreno C; Nevens F; Vanwolleghem T;
    Aliment Pharmacol Ther; 2018 Apr; 47(8):1170-1180. PubMed ID: 29498078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients.
    Chen CH; Hung CH; Wang JH; Lu SN; Hu TH; Lee CM
    Clin Microbiol Infect; 2018 Sep; 24(9):997-1003. PubMed ID: 29288020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discontinuation of lamivudine treatment in HBeAg-negative chronic hepatitis B: a pilot study with long-term follow-up.
    Karakaya F; Özer S; Kalkan Ç; Tüzün EA; Çalışkan A; Keskin O; Kabaçam G; Karatayli S; Karatayli E; Bozdayi AM; Idilman R; Yurdaydin C
    Antivir Ther; 2017; 22(7):559-570. PubMed ID: 28240596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.